|
|
|
|
||
Re: Car-T, TIL newsi have done a lot on the other board to explain how the immune response to cancer works. wish you had read it. but i will try to clarify a little for you here but you are already so far from how it works i am not sure it will help. the CAR therapies are directed at a surface antigen not a neoantigen presented to the surface on the MHC, major histocompatability complex. there are only a few surface antigens on solid tumors which are specific to that tumor, and not to other cells in the body. the CAR therapies work only on blood born cancers. cancers of the B cell lineage which all carry the CD-19 surface antigen which identifies that cell as being of the B cell lymphoid lineage. no other cells in the body carry the CD-19 surface antigen so the CAR therapies can be directed at the surface antigen CD-19 and that will kill all of the B cells i the body so the cancer will be removed along with the population of B cells. this is possible because the patient can receive replacement immunoglobulins to provide antibodies for the patient to use in an immune response since without the B cells there is no immunoglobulin production. |
return to message board, top of board |